Other languages Astria Therapeutics, Inc.

Equities

ATXS

US04635X1028

Market Closed - Nasdaq Other stock markets 01:30:00 27/06/2024 am IST			5-day change	1st Jan Change
8.99 ^USD	-0.33%		0.00%	+17.06%

21/05	Oppenheimer Adjusts Astria Therapeutics Price Target to $25 From $29, Maintains Outperform Rating	MT
09/05	Astria Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Astria Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Astria Therapeutics, Inc. Appoints Sunil Agarwal to the Board of Directors and Member of the Science and Technology Committee	09/04
Astria Therapeutics, Inc. Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE	25/03
Astria Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Astria Therapeutics Shares Rise After Pricing of $125 Million Underwritten Offering	30/01
Astria Therapeutics Files $500 Million Mixed Shelf	16/12
Astria Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Astria Therapeutics, Inc. Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting	10/11
Indian Equities End Lower on Profit Booking; IT Tops Laggards	12/23/12
Astria Therapeutics Prices Common Stock, Warrants Offering for Expected Gross Proceeds of About $64 Million	12/23/12
Glenmark Pharma Unit Licenses Antibody Portfolio to Astria Therapeutics	12/23/12
Ichnos Sciences Enters Licensing Agreement for Ox40 Antibody Portfolio with Astria Therapeutics	12/23/12
Astria Therapeutics Secures Exclusive Global License with Ichnos Sciences for OX40 Portfolio in Atopic Dermatitis Treatment	12/23/12
Astria Therapeutics, Inc. Announces Exclusive Worldwide License Agreement with Ichnos Sciences for Ox40 Portfolio	12/23/12
Astria Therapeutics, Inc. Announces Publication of Star-0215 Preclinical Data in the Journal of Pharmacology and Experimental Therapeutics	31/23/31
Astria Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/23/08
Astria Therapeutics' Genetic Disorder Drug Candidate Granted FDA Fast-Track Designation	20/23/20
Astria Therapeutics, Inc. Receives Fast Track Designation for Star-0215 for the Treatment of Hereditary Angioedema	20/23/20
Astria Therapeutics, Inc. Appoints John Ruesch as Senior Vice President, Pharmaceutical Sciences and Technical Operations	17/23/17
Astria Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Astria Therapeutics, Inc.

Equities

ATXS

US04635X1028

Other languages

Filters